Sickle Cell Screening in Adults: A Current Review of Point-of-Care Testing.

IF 1.3 Q4 HEMATOLOGY Journal of hematology Pub Date : 2024-06-01 Epub Date: 2024-06-28 DOI:10.14740/jh1272
Sebastian R Mendez-Marti, Chad Zik, Sheinei Alan, Hongkun Wang, William B Ershler
{"title":"Sickle Cell Screening in Adults: A Current Review of Point-of-Care Testing.","authors":"Sebastian R Mendez-Marti, Chad Zik, Sheinei Alan, Hongkun Wang, William B Ershler","doi":"10.14740/jh1272","DOIUrl":null,"url":null,"abstract":"<p><p>In adults, the sickle cell solubility test (SCST) is the most common screening test to determine the presence of hemoglobin S (HbS) within a blood sample. The assay is inexpensive, rapid, highly sensitive and specific. However, the SCST cannot accurately quantify the level of HbS in a test sample and requires confirmatory testing to distinguish between sickle trait and sickle cell disease. Despite these limitations, it remains the standard screening tool for HbS in a variety of settings such as screening in the US military or by the National Collegiate Athletic Association. With an increased awareness of the importance of screening for sickle cell in adults, we herein describe the current sensitivity, specificity, positive predictive value, and negative predictive value of this test. We also review overall clinical utility of this laboratory measure and briefly discuss new point-of-care techniques designed to overcome the SCST's shortcomings.</p>","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":"13 3","pages":"53-60"},"PeriodicalIF":1.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236353/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/jh1272","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In adults, the sickle cell solubility test (SCST) is the most common screening test to determine the presence of hemoglobin S (HbS) within a blood sample. The assay is inexpensive, rapid, highly sensitive and specific. However, the SCST cannot accurately quantify the level of HbS in a test sample and requires confirmatory testing to distinguish between sickle trait and sickle cell disease. Despite these limitations, it remains the standard screening tool for HbS in a variety of settings such as screening in the US military or by the National Collegiate Athletic Association. With an increased awareness of the importance of screening for sickle cell in adults, we herein describe the current sensitivity, specificity, positive predictive value, and negative predictive value of this test. We also review overall clinical utility of this laboratory measure and briefly discuss new point-of-care techniques designed to overcome the SCST's shortcomings.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人镰状细胞筛查:当前护理点检测回顾。
在成人中,镰状细胞溶解度试验(SCST)是确定血液样本中是否存在血红蛋白 S(HbS)的最常用筛查试验。该检测方法成本低廉、快速、灵敏度高且特异性强。然而,SCST 无法准确量化检测样本中的 HbS 水平,需要进行确证检测才能区分镰状特质和镰状细胞病。尽管存在这些局限性,但它仍是各种情况下 HbS 的标准筛查工具,如美国军队或全国大学生体育协会的筛查。随着人们对成人镰状细胞筛查重要性认识的提高,我们在此介绍了该检测目前的灵敏度、特异性、阳性预测值和阴性预测值。我们还回顾了这一实验室指标的总体临床效用,并简要讨论了旨在克服 SCST 不足之处的新型护理点技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of hematology
Journal of hematology HEMATOLOGY-
自引率
0.00%
发文量
29
期刊最新文献
Allogeneic Hematopoietic Stem Cell Transplantation After Solid Organ Transplantation in Patients With Hematologic Malignancies Managed With Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Controversies in the Management of Ischemic Cerebrovascular Accidents in Patients With Non-Promyelocytic Acute Myeloid Leukemia. Ferritin and Iron Levels Inversely Associated With Lymphoma Risk: A Mendelian Randomization Study. Freedom From Bleeds With Low-Dose Emicizumab Prophylaxis in Inhibitor-Positive Hemophilia A. Primary Refractory Discordant Diffuse Large B-Cell and Classical Hodgkin Lymphoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1